Adenosine A<inf>3</inf> Receptor: From Molecular Signaling to Therapeutic Strategies for Heart Diseases
Issued Date
2024-06-01
Resource Type
ISSN
16616596
eISSN
14220067
Scopus ID
2-s2.0-85195878460
Journal Title
International Journal of Molecular Sciences
Volume
25
Issue
11
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of Molecular Sciences Vol.25 No.11 (2024)
Suggested Citation
Duangrat R., Parichatikanond W., Chanmahasathien W., Mangmool S. Adenosine A<inf>3</inf> Receptor: From Molecular Signaling to Therapeutic Strategies for Heart Diseases. International Journal of Molecular Sciences Vol.25 No.11 (2024). doi:10.3390/ijms25115763 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/98883
Title
Adenosine A<inf>3</inf> Receptor: From Molecular Signaling to Therapeutic Strategies for Heart Diseases
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Cardiovascular diseases (CVDs), particularly heart failure, are major contributors to early mortality globally. Heart failure poses a significant public health problem, with persistently poor long-term outcomes and an overall unsatisfactory prognosis for patients. Conventionally, treatments for heart failure have focused on lowering blood pressure; however, the development of more potent therapies targeting hemodynamic parameters presents challenges, including tolerability and safety risks, which could potentially restrict their clinical effectiveness. Adenosine has emerged as a key mediator in CVDs, acting as a retaliatory metabolite produced during cellular stress via ATP metabolism, and works as a signaling molecule regulating various physiological processes. Adenosine functions by interacting with different adenosine receptor (AR) subtypes expressed in cardiac cells, including A1AR, A2AAR, A2BAR, and A3AR. In addition to A1AR, A3AR has a multifaceted role in the cardiovascular system, since its activation contributes to reducing the damage to the heart in various pathological states, particularly ischemic heart disease, heart failure, and hypertension, although its role is not as well documented compared to other AR subtypes. Research on A3AR signaling has focused on identifying the intricate molecular mechanisms involved in CVDs through various pathways, including Gi or Gq protein-dependent signaling, ATP-sensitive potassium channels, MAPKs, and G protein-independent signaling. Several A3AR-specific agonists, such as piclidenoson and namodenoson, exert cardioprotective impacts during ischemia in the diverse animal models of heart disease. Thus, modulating A3ARs serves as a potential therapeutic approach, fueling considerable interest in developing compounds that target A3ARs as potential treatments for heart diseases.